ID: ALA315037

Max Phase: Preclinical

Molecular Formula: C23H26N2O4S

Molecular Weight: 426.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc([C@H]2CC[C@@H](C(=O)O)N2C(=O)CNC(=O)[C@@H](S)Cc2ccccc2)cc1

Standard InChI:  InChI=1S/C23H26N2O4S/c1-15-7-9-17(10-8-15)18-11-12-19(23(28)29)25(18)21(26)14-24-22(27)20(30)13-16-5-3-2-4-6-16/h2-10,18-20,30H,11-14H2,1H3,(H,24,27)(H,28,29)/t18-,19+,20+/m1/s1

Standard InChI Key:  LQAZEFOQORVDKT-AABGKKOBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 426.54

Molecular Weight (Monoisotopic): 426.1613

AlogP: 2.77

#Rotatable Bonds: 7

Polar Surface Area: 86.71

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.90

CX Basic pKa:

CX LogP: 3.16

CX LogD: -0.06

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.59

Np Likeness Score: -0.42

References

1. Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP..  (1996)  Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.,  39  (13): [PMID:8691458] [10.1021/jm950783c]

Source

Source(1):

• Scientific Literature